Efficacy, Safety, and PopPK Profile of ABP-745 in Patients With Atherosclerosis

Summary

This is a multicenter, randomized, double-blind, placebo parallel controlled study to evaluate the preliminary efficacy, safety, and PopPK profile of ABP-745 in patients with ASCVD. Efficacy of ABP-745 in reducing atherosclerotic plaque compared with placebo will be evaluated in participants with ASCVD. The primary efficacy measurement will be assessed at 52W of treatment.

Timeline

Start

2026-04-23

Primary completion

2028-01

Completion

2028-04

Drugs

Indications